Fingerprint
Dive into the research topics of 'Long-term follow-up results of the multicenter phase II trial of regorafenib in patients with metastatic and/or unresectable GI stromal tumor after failure of standard tyrosine kinase inhibitor therapy'. Together they form a unique fingerprint.- Sort by
- Weight
- Alphabetically